Patent Yard Sign in
Canadian application, no grantCanada

Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation

CA 2345477 A1 · Owner: Nicolette, Charles A. · Inventors: Nicolette, Charles A.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The present invention provides novel synthetic antigenic peptide epitopes related to IGF-II-R. These synthetic antigenic peptide epitopes are designed for enhanced binding to MHC molecules, and have enhanced immunoregulatory properties relative to their natural counterparts. The synthetic antigenic peptide epitopes of the invention are useful in a variety of methods of modulating an immune response to the synthetic antigenic peptide epitopes and thus to the corresponding native antigenic determinant. Synthetic antigenic peptide epitopes of the invention thus find application in a wide variety of immunomodulatory protocols, including methods to induce or increase an immune response, …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed October 4, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 4, 2019.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 4, 2021.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledOctober 4, 1999
GrantedNo grant recorded
Term endedOctober 4, 2019
Patent numberCA 2345477 A1
Classification (IPC)C12N15/12 +2 more

Timeline

Timeline From CIPO dates

2000200220042006200820102012201420162018Application filedOct 4, 1999Term endedOct 4, 2019

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.